Literature DB >> 1676512

A high-performance liquid chromatographic assay for the enantiomers of bevantolol in human plasma.

S E Rose1, E J Randinitis.   

Abstract

A method was developed and validated for the simultaneous analysis of (+)- and (-)-bevantolol in human plasma. The assay involves plasma protein precipitation, derivatization of racemic bevantolol to its diastereomeric thioureas with 2,3,4,5-tetra-o-acetyl-alpha-D-glucopyranosyl isothiocyanate, and solid-phase extraction of the diastereomers from 0.5 ml human plasma. Chromatographic separation was accomplished under isocratic conditions using a reversed-phase C-18 analytical column and mobile phase consisting of equal parts of 75 mM dibasic ammonium phosphate buffer (adjusted to pH 3.5 with phosphoric acid) and acetonitrile, with a detection wavelength of 220 nm. The absolute peak-height method was employed for quantitation. Retention times for the diastereomers of (+)- and (-)-bevantolol were 7.4 and 6.4 min, respectively. The method is suitable for the quantification of the enantiomers over a concentration range of 40 to 800 ng/ml per enantiomer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676512     DOI: 10.1023/a:1015858219018

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Cardioselective beta-adrenergic blocking agents. 1. 1-((3,4-Dimethoxyphenethyl)amino)-3-aryloxy-2-propanols.

Authors:  M L Hoefle; S G Hastings; R F Meyer; R M Corey; A Holmes; C D Stratton
Journal:  J Med Chem       Date:  1975-02       Impact factor: 7.446

2.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

3.  Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma.

Authors:  B Silber; S Riegelman
Journal:  J Pharmacol Exp Ther       Date:  1980-12       Impact factor: 4.030

4.  Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin.

Authors:  U K Walle; T Walle; S A Bai; L S Olanoff
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

5.  Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.

Authors:  M S Lennard; G T Tucker; J H Silas; S Freestone; L E Ramsay; H F Woods
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

6.  Stereoselective clearance and distribution of intravenous propranolol.

Authors:  L S Olanoff; T Walle; U K Walle; T D Cowart; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

7.  The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.

Authors:  A M Barrett; V A Cullum
Journal:  Br J Pharmacol       Date:  1968-09       Impact factor: 8.739

8.  Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.

Authors:  T Walle; U K Walle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.